Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression.
about
A cannabinoid 2 receptor agonist attenuates bone cancer-induced pain and bone lossTargeting microRNAs as key modulators of tumor immune responseDevelopment, Maintenance, and Reversal of Multiple Drug Resistance: At the Crossroads of TFPI1, ABC Transporters, and HIF1Exploiting the Immunomodulatory Properties of Chemotherapeutic Drugs to Improve the Success of Cancer ImmunotherapyNeoplastic "Black Ops": cancer's subversive tactics in overcoming host defensesmiRNA-mRNA integrated analysis reveals roles for miRNAs in primary breast tumorsFormation and role of exosomes in cancer.uPAR induces expression of transforming growth factor β and interleukin-4 in cancer cells to promote tumor-permissive conditioning of macrophages.The chemokine CXCL16 and its receptor, CXCR6, as markers and promoters of inflammation-associated cancers.Il-6 signaling between ductal carcinoma in situ cells and carcinoma-associated fibroblasts mediates tumor cell growth and migrationMCentridFS: a tool for identifying module biomarkers for multi-phenotypes from high-throughput data.Cell-composition effects in the analysis of DNA methylation array data: a mathematical perspective.Imagable 4T1 model for the study of late stage breast cancer.A murine preclinical syngeneic transplantation model for breast cancer precision medicine.Immunophenotypic features of tumor infiltrating lymphocytes from mammary carcinomas in female dogs associated with prognostic factors and survival ratesHigh STAT1 mRNA levels but not its tyrosine phosphorylation are associated with macrophage infiltration and bad prognosis in breast cancer.The innate and adaptive infiltrating immune systems as targets for breast cancer immunotherapy.PTGS2 and IL6 genetic variation and risk of breast and prostate cancer: results from the Breast and Prostate Cancer Cohort Consortium (BPC3).Breast cancer and the immune systemPreferential accumulation of regulatory T cells with highly immunosuppressive characteristics in breast tumor microenvironment.Cancer inflammation and regulatory T cells.The inflammatory microenvironment in colorectal neoplasia.Polymerase incorporation and miscoding properties of 5-chlorouracil.Estrogen Receptor-β and the Insulin-Like Growth Factor Axis as Potential Therapeutic Targets for Triple-Negative Breast Cancer.A Novel Unsupervised Algorithm for Biological Process-based Analysis on Cancer.Chitosan-based thermoreversible hydrogel as an in vitro tumor microenvironment for testing breast cancer therapies.Local regulation of human breast xenograft models.Genetic variants in interleukin genes are associated with breast cancer risk and survival in a genetically admixed population: the Breast Cancer Health Disparities Study.Beneficial bacteria stimulate host immune cells to counteract dietary and genetic predisposition to mammary cancer in mice.Oral delivery of PND-1186 FAK inhibitor decreases tumor growth and spontaneous breast to lung metastasis in pre-clinical models.Mammalian target of rapamycin activator RHEB is frequently overexpressed in human carcinomas and is critical and sufficient for skin epithelial carcinogenesisCytokine and cytokine receptor genes of the adaptive immune response are differentially associated with breast cancer risk in American women of African and European ancestryPhysical activity and breast cancer survival: an epigenetic link through reduced methylation of a tumor suppressor gene L3MBTL1.Increased NOS2 predicts poor survival in estrogen receptor-negative breast cancer patients.The tumor microenvironment of colorectal cancer: stromal TLR-4 expression as a potential prognostic markerImmunoglobulin kappa C predicts overall survival in node-negative breast cancer.TFPI alpha and beta regulate mRNAs and microRNAs involved in cancer biology and in the immune system in breast cancer cells.Prognostic and diagnostic value of spontaneous tumor-related antibodiesImpact of CD68/(CD3+CD20) ratio at the invasive front of primary tumors on distant metastasis development in breast cancerComparison of immunity in mice cured of primary/metastatic growth of EMT6 or 4THM breast cancer by chemotherapy or immunotherapy
P2860
Q24615787-3510EACA-E65D-45BD-9878-EF332F8A889CQ26746972-654C46B2-F727-4593-8F13-4D5F9D2DBFA0Q26778957-475CDD7C-598F-4F4B-9D47-0028400AE96CQ26779184-63A49C6D-26F1-4272-A47A-44822F5CB463Q27001081-882DEEC7-C4D7-4C59-930A-6F6A205A266FQ28742532-6B9518C7-76D8-42A8-9AD2-8843CCE9A315Q30303067-391470D5-49DD-4197-BFC7-0A4655400093Q30365899-0600929A-789B-4206-BE5B-A4DE4C6FCC0BQ30438926-1DB716CB-1C50-4FF6-BAC3-D7CCEEDF9E2AQ30660919-E622AF95-3577-4D27-BA7B-C7CE398C257BQ30841031-05A67156-33F0-4BA5-B5A0-B3D9AD46FC5FQ30935846-24118B2A-E6A5-4CC3-AF3C-CE539C540091Q33358981-A2A3CBC3-DB11-4EAF-8A77-0BC0989929CBQ33580224-2B96ECE2-9A6C-45D4-92C5-B33531DD2331Q33595267-96407F56-AEA3-4B3D-938C-95BA579F08CCQ33611598-3E3F0876-38D4-4B3D-9BC4-8F0890A3F24EQ33660069-73A69E63-8E09-4B7A-92D9-B20D2EFCC3DEQ33705238-55E18AB9-A036-443E-BD4D-23136EDC4A45Q33753043-A80AFC01-49AD-432A-B24F-A84F5A65F9E6Q33779401-C9E73764-C68A-4D86-9C76-CB031FD1ADB3Q33796582-8336BCCD-377B-4124-BE97-6142BFF414D8Q33797695-7BA376F7-230A-43ED-AB72-6C1CFED67BDBQ33798330-D63020C3-91B9-4AD0-A992-5DD51B5E2F82Q33866151-84AA98E1-5CC4-4839-88F3-D3A69BAC2289Q33875947-3AD7B9BB-8D5B-425F-9BA2-67C6BCC3363DQ33894643-48D07C36-909E-4CBA-9114-D6CB16AB0821Q33964451-DEB1E1EF-41A7-4B75-ADA6-111FAC26D21FQ34009975-5A001F15-705B-48D3-A830-7AF49F383CFDQ34039445-949451E5-C55C-4F80-9449-5857807E1F4BQ34103876-D928BD99-FAD7-4982-97FA-CFCC2FA7B6D7Q34109970-894BF080-6A37-4AAA-B925-7B35CC952E65Q34155082-846CED16-8AFA-4516-928E-B29C0968B5EBQ34207667-473B7F6F-FE9F-408D-A056-E80FB2A3BE8AQ34245323-DBB6F550-1014-4BE1-821E-FD9825038724Q34380094-5A404C42-4514-4C56-8859-1ABBE99FC0FCQ34427347-07E95849-AB54-46A9-B4EA-120B95D11437Q34448038-F47BF162-2D40-4E52-ABEE-21C0382DC6AEQ34475795-8DBE1FEA-892C-45B6-ACA5-F1A35DA95E3CQ34541239-65924409-33E1-4A29-A5A3-3FD13712900DQ34542545-96592FD3-49E0-489D-B85E-41CA1A845661
P2860
Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Inflammation and breast cancer ...... ing breast cancer progression.
@ast
Inflammation and breast cancer ...... ing breast cancer progression.
@en
type
label
Inflammation and breast cancer ...... ing breast cancer progression.
@ast
Inflammation and breast cancer ...... ing breast cancer progression.
@en
prefLabel
Inflammation and breast cancer ...... ing breast cancer progression.
@ast
Inflammation and breast cancer ...... ing breast cancer progression.
@en
P2860
P921
P356
P1476
Inflammation and breast cancer ...... ing breast cancer progression.
@en
P2093
David G DeNardo
Lisa M Coussens
P2860
P2888
P356
10.1186/BCR1746
P577
2007-01-01T00:00:00Z
P5875
P6179
1002958592